RAPT Q4 2020 Earnings — RAPT Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RAPTRAPT Therapeutics, Inc.

$959M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

$1M100.0% margin

Operating Income

-$13M-1005.0% margin

Net Income

-$13M-978.1% margin

EPS (Diluted)

$-4.14

QoQ Revenue Growth

-14.8%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$16M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$119M

Total Liabilities

$15M

Stockholders' Equity

$104M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	$1M	$0	—
Operating Income	-$13M	-$13M	-2.1%
Net Income	-$13M	-$13M	+3.6%